KLTO.Klotho Neurosciences, INC

8-K: Redwoods Acquisition Corp. Announces ANEW Medical Re-Audit and Business Combination Update

Sentiment:

8-K Filing

📋All filings for Klotho Neurosciences, INC
🔒Login to Follow

Redwoods Acquisition Corp. has filed an 8-K report detailing a re-audit of ANEW Medical's financials and providing an update on their business combination agreement.

Capital raiseThe company has issued convertible promissory notes totaling $4,000,000 that will fund upon closing of the business combination.The company sold 50,000 shares of Series D Preferred Stock for $125,000.The company granted 100,000 shares of Series D Preferred Stock as a commitment fee.
Worse than expectedThe company has a history of recurring losses and has not achieved profitable operations.The company's original auditor was barred from practicing before the SEC, requiring a re-audit of financial statements.The company has a significant accumulated deficit of $4,597,632 since inception.

Summary

  • Redwoods Acquisition Corp. is proceeding with its business combination with ANEW Medical, Inc.
  • The original audited financial statements of ANEW for 2022, prepared by B.F. Borgers, were deemed invalid after the auditor was barred from practicing before the SEC.
  • ANEW engaged Yusufali & Associates, LLC to re-audit the 2022 financials, audit the 2023 financials, and review the unaudited financials for the quarter ended March 31, 2024.
  • The re-audited and reviewed financial statements are included as exhibits in the 8-K filing.
  • The business combination is expected to close in May 2024, pending stockholder approval and Nasdaq listing approval.
  • ANEW Medical has incurred losses of $707,458 in 2023 and $598,593 in 2022.
  • ANEW Medical has accumulated losses of $4,597,632 since inception.
  • The company has acquired licenses and patents valued at $2,309,554 as of March 31, 2024.
  • The company has a note payable of $1,332,270 as of March 31, 2024.
  • The company has issued convertible promissory notes totaling $4,000,000 that will fund upon closing of the business combination.

Sentiment

Score: 4

Explanation: The document highlights significant financial losses and the need for a re-audit, which are negative indicators. However, the progress towards the business combination and the securing of new financing provide some positive aspects. Overall, the sentiment is cautiously negative.

Positives

  • The business combination with Redwoods Acquisition Corp. is progressing towards completion.
  • ANEW Medical has secured new financing through convertible promissory notes totaling $4,000,000.
  • The company has a portfolio of licenses and patents valued at $2,309,554 as of March 31, 2024.

Negatives

  • ANEW Medical has a history of recurring losses and has not achieved profitable operations.
  • The company's original auditor was barred from practicing before the SEC, requiring a re-audit of financial statements.
  • The company has a significant accumulated deficit of $4,597,632 since inception.
  • The company has a note payable of $1,332,270 as of March 31, 2024.

Risks

  • The business combination is subject to stockholder approval and Nasdaq listing approval.
  • There is a risk that the business combination may not be completed.
  • ANEW Medical's ability to continue as a going concern is uncertain due to recurring losses.
  • The company's financial statements may be subject to further adjustments.
  • The company has a significant accumulated deficit of $4,597,632 since inception.

Future Outlook

The business combination between Redwoods and ANEW is expected to close in May 2024, pending stockholder and Nasdaq approvals. The combined company will focus on developing and commercializing biologic medicines and gene therapies.

Industry Context

The document reflects the ongoing trend of SPAC mergers in the biotech and pharmaceutical sectors, where companies seek to go public through acquisitions. The re-audit highlights the importance of regulatory compliance and the risks associated with using auditors who are not in good standing with the SEC.

Comparison to Industry Standards

  • The financial performance of ANEW Medical, with its significant accumulated losses, is not uncommon for development-stage biotech companies.
  • Many early-stage biotech companies rely on external funding and incur substantial losses while developing their technologies.
  • The reliance on licensing agreements and the acquisition of patents is a typical strategy for biotech companies seeking to build a portfolio of intellectual property.
  • The use of convertible promissory notes for financing is a common practice for companies in this sector, especially those pursuing a SPAC merger.

Related Party Transactions

  • The company has related party payables of $185,000 as of March 31, 2024.
  • The company's CEO is owed $100,000 under his employment agreement as of March 31, 2024.
  • A director and officer of the company is owed $85,000 under a consulting agreement as of March 31, 2024.

Stakeholder Impact

  • Shareholders of Redwoods and ANEW will be impacted by the business combination.
  • Employees of ANEW will be impacted by the merger.
  • Customers and partners of ANEW will be impacted by the merger.
  • Creditors of ANEW will be impacted by the merger.

Next Steps

  • The company needs to obtain stockholder approval for the business combination.
  • The company needs to secure approval from the Nasdaq Stock Market for the listing of the combined company.
  • The company needs to complete the closing conditions for the business combination.
  • The company needs to continue developing and commercializing its licensed technologies.

Key Dates

DateDescription
February 27, 2006Strategic Asset Leasing, Inc. was incorporated in Nevada.
March 5, 2013Strategic Asset Leasing, Inc. changed its domicile to Wyoming.
December 14, 2020Dr. Joseph Sinkule purchased shares of Series C preferred stock and became CEO.
November 1, 2021Agreement and Plan of Merger with Anew Acquisition Corp was executed and name change to ANEW Medical, Inc. was approved.
January 4, 2022Articles of Amendment filed with the State of Wyoming, changing its name to ANEW Medical, Inc.
September 12, 2022ANEW Medical acquired market-approved anti-cancer drugs for $1,386,766.
May 30, 2023Business Combination Agreement with Redwoods Acquisition Corp. was entered into.
February 14, 2024Redwoods' registration statement on Form S-4 was declared effective by the SEC.
March 1, 2024Certificate of Designation filed to authorize Series D Preferred Stock.
March 4, 202450,000 shares of Series D Preferred Stock sold for $125,000.
March 28, 2024Securities Purchase Agreements signed for $2,000,000 in convertible promissory notes.
April 22, 2024Company signed a $2,000,000 convertible promissory note with an investor.
June 20, 2024Date of the 8-K report.

Keywords

business combination, re-audit, financial statements, ANEW Medical, Redwoods Acquisition Corp, merger, SPAC, biologics, gene therapy, pharmaceuticals, licenses, patents

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.